http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. (HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said Friday. http://medicalxpress.com/news/2013-01-gleevec-latest-pediatric-cancer.html Cancer Fri, 25 Jan 2013 16:55:35 EST news278355318 The U.S. Food and Drug Administration (FDA) this month expanded the options for patients with chronic myeloid leukemia and one form of acute lymphoblastic leukemia that carries the Philadelphia chromosome (Ph+ALL). It approved the drug ponatinib (Iclusig), which is effective in a significant number of patients with either disease. http://medicalxpress.com/news/2012-12-options-cml-patients-drugs.html Cancer Fri, 21 Dec 2012 16:54:47 EST news275331280 (HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia.. http://medicalxpress.com/news/2012-12-iclusig-rare-leukemias.html Cancer Sun, 16 Dec 2012 15:20:01 EST news274892932 Huntsman Cancer Institute (HCI) researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic lymphoma (Ph+ ALL). The New England Journal of Medicine released results of the trial today. http://medicalxpress.com/news/2012-11-clinical-trial-good-results-leukemia.html Cancer Fri, 30 Nov 2012 09:10:17 EST news273489005 A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine. http://medicalxpress.com/news/2012-11-ponatinib-resistant-chronic-myeloid-leukemia.html Cancer Wed, 28 Nov 2012 17:00:21 EST news273343855 Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies. http://medicalxpress.com/news/2012-08-drugs-treatment-options-high-risk-childhood.html Cancer Mon, 13 Aug 2012 12:52:00 EST news264081090 (HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with a rare form of blood and bone marrow cancer, Philadelphia chromosome negative acute lymphoblastic leukemia, abbreviated ALL. http://medicalxpress.com/news/2012-08-marqibo-rare-leukemia.html Cancer Fri, 10 Aug 2012 05:18:36 EST news263794709 (HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with Philadelphia chromosome negative acute lymphoblastic leukemia (ALL). http://medicalxpress.com/news/2012-08-marqibo-ph-acute-lymphoblastic-leukemia.html Medications Fri, 10 Aug 2012 05:16:47 EST news263794597 About one in five or six cases of adult leukaemia in Western populations relates to so-called chronic myeloid leukaemia, or CML. Treatment of CML usually relies on inhibitors of the abnormal protein that causes the condition but some patients do not respond to treatment and efforts are underway to develop a supplementary approach, targeting the so-called JAK2 kinase. Recent results from the groups of Veronika Sexl at the University of Veterinary Medicine, Vienna (Vetmeduni Vienna) and Giulio Superti-Furga at the Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM) have called this strategy into question. The work is published in the current issue of the prestigious journal Nature Chemical Biology and is of immediate relevance to leukaemia treatment. http://medicalxpress.com/news/2012-01-jak-leukaemia-therapy.html Cancer Mon, 30 Jan 2012 10:18:39 EST news247141110 Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML. Blocking this growth factor increases the life expectancy of these mice, even in those resistant to imatinib. http://medicalxpress.com/news/2011-06-efficient-therapy-specific-leukemia.html Cancer Tue, 14 Jun 2011 10:01:28 EST news227264422